Showing 1691-1700 of 2123 results for "".
- Epilepsy Essentials: Exploring the Mysterious Link Between Sleep and Epilepsyhttps://practicalneurology.com/diseases-diagnoses/epilepsy-seizures/PN0305Epilepsy-pdf/31479/Sleep plays a crucial role in overall health, occupying about one-third of our lives. In the medical field, particularly among physicians and nurses, sleep deprivation is recognized for its detrimental effects on cognitive functions such as memory, attention, and concentration, which can lead to inc
Prescription Medical Food for Alzheimer's: A Novel Approach to Neurologic Disease
https://practicalneurology.com/diseases-diagnoses/alzheimer-disease-dementias/prescription-medical-food-for-alzheimers-a-novel-approach-to-neurologic-disease/30717/The potentially confusing category of medical foods may present options for disease management.- Therapeutics Q&Ahttps://practicalneurology.com/columns/practice-management/therapeutics-qa/31184/Integrating Antidepressant Therapy in Parkinson’s Disease ManagementDepression is a common comorbidity in Parkinson’s disease (PD) patients, necessitating careful consideration for antidepressant therapy. Dr. Eric J. Ahlskog, a leading neurologist at the Mayo Clinic, emphasizes the interplay between
- Will Generics Gobble Up The Neurology Market?https://practicalneurology.com/columns/practice-management/will-generics-gobble-up-the-neurology-market/31082/Generics Gain Ground in Neurology: Implications for Clinical PracticeThe landscape of neurology pharmacotherapy is shifting as generic medications increasingly replace brand-name drugs, promising substantial cost savings without compromising efficacy. As highlighted in the December 2007 issue of *Pr
- Movement Disorders Focushttps://practicalneurology.com/diseases-diagnoses/movement-disorders/pn0407-movemntdis-pdf/31190/Tardive Dyskinesia: Overview, Causes, and ManagementTardive dyskinesia (TD) represents a complex group of involuntary, repetitive movements primarily resulting from prolonged use of dopamine-receptor antagonists (DRAs), including both typical and atypical antipsychotic medications. TD is characteriz
- Business Advisorhttps://practicalneurology.com/columns/practice-management/business-advisor/31332/In the realm of neurology, demonstrating patient health improvements necessitates robust qualitative measurements. Clinicians often rely on tools such as MRI comparisons, seizure frequency assessments, and evaluations of Parkinson’s “off” times to establish a baseline against which future treatments
- Therapeutics Q&Ahttps://practicalneurology.com/columns/practice-management/therapeutics-qa/31470/The April 2005 issue of *Practical Neurology* addresses the increasing trend of generic substitution for antiepileptic drugs (AEDs) and the significant concerns it raises among healthcare professionals. While generic AEDs are not as widely substituted as other drug classes, their use is becoming mor
- Bad Reception: When MS Patients Are on a Different Wavelengthhttps://practicalneurology.com/columns/practice-management/bad-reception-when-ms-patients-are-on-a-different-wavelength/31064/Enhancing Physician-Patient Relationships to Improve MS Patient RetentionMaintaining strong physician-patient alliances is crucial in managing Multiple Sclerosis (MS), a chronic and unpredictable neurological disorder. According to a January 2008 article in Practical Neurology, MS patients frequentl
- Business Advisorhttps://practicalneurology.com/columns/practice-management/business-advisor/31120/In the September 2007 issue of *Practical Neurology*, Mary McDermott addresses a critical concern for neurologists: how to secure appropriate compensation for the increasing time spent with patients, particularly within an aging and chronically ill population. The article highlights the potential of
- Editor's Messagehttps://practicalneurology.com/columns/practice-management/editors-message/31343/In the February 2006 issue of *Practical Neurology*, Editor-in-Chief Jack Persico addresses the pressing challenges facing the healthcare sector, particularly in the realm of neurology. Central to his discussion is the recent five percent reduction in Medicare reimbursements, a change that has intro